Glial- and Neuronal-Specific Expression of CCL5 mRNA in the Rat Brain

Maria Fe Lanfranco1,2, Italo Mocchetti1,2*, Mark P. Burns2 and Sonia Villapol2

1Laboratory of Preclinical Neurobiology, Georgetown University Medical Center, Washington, DC, United States,
2Department of Neuroscience, Georgetown University Medical Center, Washington, DC, United States

Chemokine (C-C motif) ligand 5 (CCL5) belongs to a group of chemokines that play a role in the peripheral immune system, mostly as chemoattractant molecules, and mediate tactile allodynia. In the central nervous system (CNS), CCL5 and its receptors have multiple functions, including promoting neuroinflammation, insulin signaling, neuromodulator of synaptic activity and neuroprotection against a variety of neurotoxins. Evidence has also suggested that this chemokine may regulate opioid response. The multifunctional profile of CCL5 might correlate with its ability to bind different chemokine receptors, as well as with its unique cellular expression. In this work, we have used fluorescence in situ hybridization combined with immunohistochemistry to examine the expression profile of CCL5 mRNA in the adult rat brain and provide evidence of its cellular localization. We have observed that the highest expression of CCL5 mRNA occurs in all major fiber tracts, including the corpus callosum, anterior commissure, and cerebral peduncle. In these tracts, CCL5 mRNA was localized in oligodendrocytes, astrocytes and microglia. Astrocytic and microglial expression was also evident in several brain areas including the cerebral cortex, caudate/putamen, hippocampus, and thalamus. Furthermore, using a specific neuronal marker, we observed CCL5 mRNA expression in discrete layers of the cortex and hippocampus. Interestingly, in the midbrain, CCL5 mRNA co-localized with tyrosine hydroxylase (TH) positive cells of the ventral tegmental area, suggesting that CCL5 might be expressed by a subset of dopaminergic neurons of the mesolimbic system. The expression of CCL5 mRNA and protein, together with its receptors, in selected brain cell populations proposes that this chemokine could be involved in neuronal/glial communication.

Keywords: astrocytes, corpus callosum, cerebral cortex, dopamine, hippocampus, in situ hybridization, oligodendrocytes, ventral tegmental area

INTRODUCTION

Chemokines belong to the cytokine family of peptides that induce the maturation and trafficking of leukocytes and are considered to be essential for the inflammatory responses of the immune system. Some chemokines have been linked to pro-inflammatory events, associated with chronic pain (White et al., 2005) or brain diseases such as human immunodeficiency virus (HIV)-associated encephalitis.
dementia (Schmidt Mayerova et al., 1996; Conant et al., 1998), multiple sclerosis (Hvas et al., 1997; McManus et al., 1998; Rentzos et al., 2007), stroke (Siniscalchi et al., 2014) or traumatic brain injury (Villapol et al., 2017).

Of particular interest is the chemokine (C-C motif) ligand 5 (CCL5), formerly known as Regulated on Activation Normal T-cell Expressed and Secreted (RANTES). CCL5 is a small protein of 68 amino acids that activate mononuclear phagocytes and induce their migration across the blood brain barrier to the site of inflammation (Ubogu et al., 2006). The role of CCL5 in inflammation has also been inferred by an association between increased CCL5 protein expression and the degree of inflammation in a variety of disorders and pathologies, including neuropathic pain (Bhangoo et al., 2007), asthma, atherosclerosis and arthritis among others (Marques et al., 2013). However, in the brain, CCL5 function goes beyond the one attributed to a classic pro-inflammatory chemokine. In fact, CCL5 is capable of inducing proliferation of Oli-neu, an oligodendrocyte precursor-like cell line (Kadi et al., 2006) suggesting a role in myelination. Moreover, CCL5 promotes the migration of dorsal root ganglia cells in vitro (Bolin et al., 1998), and regulates the differentiation of astrocytes (Bakhiet et al., 2001) suggesting that CCL5 may act as a neurotrophic factor. In addition, ex vivo activation of CCL5 receptor (CCR5) by CCL5 increases glucose transporter type 4 membrane translocation in the hypothalamus (Chou et al., 2016), suggesting a role of CCL5 in glucose uptake and metabolism. These examples highlight the potential role of CCL5 as a modulator of cellular metabolism and brain architecture. Lastly, CCL5 exerts neuroprotective activity against various neurotoxins including glutamate (Bruno et al., 2000), β-amyloid (Ignatov et al., 2006), and the HIV proteins gp120 (Campaign et al., 2015) and tat (Rozzi et al., 2014). The different effects of CCL5 could be due to the ability of this chemokine to bind to multiple receptors. The selective and differential expression of CCL5 and its receptors, CCR5 (Avdoshina et al., 2011), CCR3 (He et al., 1997) and CCR1 (Tran et al., 2007) in the rodent brain supports the role of CCL5 as a potential modulator of brain homeostasis. Nevertheless, the functional role of CCL5 in the brain could be more in line with the suggested properties of some chemokines to act as a third neurotransmitter system (Adler et al., 2005) helping neuronal communication (Rostene et al., 2007), perhaps through modulation of the release of glutamate from nerve endings (Musante et al., 2008).

CCL5 is constitutively expressed in the adult central nervous system (CNS; Campbell et al., 2013). Nevertheless, the type of cells that express CCL5 has been so far inferred by in vitro studies. For instance, astrocytes appear to express CCL5 at high levels (Avdoshina et al., 2010); nevertheless, oligodendrocytes (Balabanov et al., 2007), microglia (Avdoshina et al., 2010) and neurons (Mocchetti et al., 2013), all release CCL5. In this study, we have analyzed CCL5 mRNA expression patterns in the rat brain using in situ hybridization combined with immunohistochemistry to detect specific cell types (Grabinski et al., 2015; Lanfranco et al., 2017). This method showed adequate sensitivity and specificity to detect mRNA transcripts of the CCL5 gene. Our results show that CCL5 mRNA follows a cellular and anatomical distribution, which is highly regionalized and restricted to certain parts of the brain. We provide evidence for the first time that CCL5 mRNAs can be expressed in dopamine-producing neurons.

MATERIALS AND METHODS

Animals

Two month-old C57BL/6j (wild-type, WT) and CCL5 knock-out (KO, B6.129P2-Ccl5tm1) male mice (22–25 g) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). CCL5 KO mice have been validated by northern blot analysis of total RNA isolated from LPS-stimulated peritoneal exudate cells (Makino et al., 2002). Three-month-old male Sprague-Dawley (SD) rats (225–250 g) were purchased from Charles River Laboratory (Germantown, MD, USA). Animals were housed under standard conditions with food and water ad libitum and maintained on a 12-h light/dark cycle. Animals were anesthetized with a mixture of ketamine/xylazine (80 mg/kg and 10 mg/kg, i.p.) and intracardially perfused with ice-cold phosphate buffered saline (PBS) followed by perfusion with 4% paraformaldehyde (PFA). After perfusion, whole brains were quickly removed and post-fixed in 4% PFA overnight and transferred sequentially into a 10%, 20% and 30% sucrose solution. Post-fixed brains were used for RNA in situ hybridization and immunohistochemistry studies. All studies were carried out following the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health and approved by Georgetown University Animal Care and Use Committee.

RNAseq® in Situ Hybridization Combined with Immunohistochemistry

A sliding microtome (microm HM 430, Thermo Fisher Scientific, Tustin, CA, USA) was used to cut the brains in coronal orientation. The brain sections (20 μm thickness) were cryoprotected in an antifreeze solution (30% glycerol + 30% ethylene glycol + 0.01 M PBS) for storage at −20°C. Free-floating brain sections were washed three times in PBS before mounting in Gold SealTM UltraStickTM Adhesion Microscope Slides (Cat No. 3039-002, Thermo Fisher Scientific). Tissue was allowed to dry at room temperature (RT) and then stored at −20°C until use. RNAseq® in situ hybridization assay was performed according to manufacturer’s instructions (Advance Cell Diagnostics (ACD), Hayward, CA, USA). In short, mounted tissue sections were serially dehydrated in 50%, 70%, 95%, 100% and 100% ethanol for 5 min each. In between all pretreatment steps, tissue sections were briefly washed with ultra-pure water. Incubation periods were performed on the HybEx™ hybridization system (ACD). The pretreat solution 1 (hydrogen peroxide reagent) was applied for 10 min at RT and then the tissue sections were boiled in pretreat solution 2 (target retrieval reagent) for 15 min. Mounted slices were treated with pretreat solution 3 (protease reagent) for 30 min at 40°C. Custom rat CCL5 RNAseq® probe was designed and
purchased from ACD. CCL5 probe targets the region 14-556 (Accession number: NM_031116.3) of the CCL5 sequence with 12 pairs of ZZ-target probes. In addition, the negative (Cat. No. 310043, ACD) and positive (Cat. No. 313911, ACD) control probes were applied and let hybridized for 2 h at 40°C. The amplification steps were performed according to manufacturer’s directions. In between every amplification step, sections were washed with 1× wash buffer. Detection was performed using a mixture ratio of Red-A to Red-B solution of 1:60. The sections were incubated for 10 min at RT and rinsed with ultra-pure water.

Following in situ hybridization, the sections were processed for immunohistochemistry. Briefly, following the blocking step with 5% normal goat serum (NGS) in PBS for 1 h at RT, post-hybridized slides were incubated with an antibody against glial fibrillary acidic protein (GFAP, 1:1000, EMD Millipore, Temecula, CA, USA), ionized calcium binding adaptor molecule-1 (Iba-1, 1:500, Wako Chemical USA, Richmond, VA, USA), homeobox transcription factor Nkx2.2 (1:100, EMD Millipore), neuronal nuclear antigen (NeuN, 1:100, EMD Millipore) or tyrosine hydroxylase (TH, 1:500, EMD Millipore) in the presence of 2% NGS in PBS overnight at 4°C. Brain sections treated with NeuN antibody were incubated for 72 h at 4°C. Subsequent to three washes with PBS, the slides were incubated with corresponding Alexa Fluor® 488 secondary antibodies (1:500; Molecular probes®, Thermo Fisher Scientific) for 2 h at RT. Brain sections were rinsed with PBS three times and incubated for 5 min in PBS with DAPI solution (1:50,000, Sigma-Aldrich, St. Louis, MO, USA) for counterstained nuclei.

Images Acquisition and Quantitative Analysis

Anatomical structures were analyzed in coronal sections and mapped according to Paxinos and Watson atlas (Paxinos and Watson, 1998). Fluorescent signals of CCL5 mRNA hybridization and immunohistochemistry for different cell types were imaged with a 10×, 20×, 40× and 63× objective lens on a Leica SP8 confocal microscope (Leica Microsystems Inc., Buffalo Grove, IL, USA) and an Axioplan 2 microscope (Zeiss, Thorwood, NY, USA) with a Photometrics camera. All microscope and camera settings were identical for all images. The color label to far red (Excitation 647 nm, Emission 690 nm) was assigned for mRNA hybridization signal. The color label to green was assigned for the antigen of interest (Excitation 490 nm, Emission 525 nm). The number of CCL5 mRNA positive/cell was quantified in five (corpus callosum and cortex) and three (hippocampus and VTA) microscopic fields per brain section (20X, 151.894 mm²), using the ImageJ64 software (National Institute of Health. Bethesda, MD, USA), as previously described (Villapol et al., 2017).

Statistical Analysis

Figures for RNAscope and IHC are representative of sections obtained from three animals. Data for Figure 4, expressed as the mean ± SEM (sections obtained from five animals), were analyzed using one-way analysis of variance (ANOVA) with Bonferroni’s multiple comparison post hoc test using GraphPad Prism software v.5.0 (Graphpad). A p-value < 0.05 was considered statistically significant.

RESULTS

Validation of CCL5 mRNA Probe

Several antibodies against CCL5 exhibit non-specific binding to an antigen as determined by positive reactions in brain sections from WT and CCL5 KO mice (Supplementary Figure S1). Thus, we used in situ hybridization to map the expression of CCL5 mRNA. Rat and mouse CCL5 mRNA share high sequence similarity (>90%). Therefore, we first validated the specificity of the CCL5 probe for RNAscope® by comparing CCL5 mRNA signal in brain sections from WT and CCL5 KO mice. In the cortex (Figure 1A) and corpus callosum (Figure 1D) of WT mice, the CCL5 probe produced a strong fluorescent signal, characterized by red dots co-localizing with DAPI positive cells (insets in Figures 1A,D), suggesting a nuclear localization. Moreover, we observed that only a subpopulation of cells expresses CCL5 mRNA, evidenced by the lack of red puncta in several DAPI-stained nuclei (Figures 1A,D). No
hybridization was observed in CCL5 KO mice (Figures 1B,E), supporting the specificity of the CCL5 mRNA probe used for RNAscope®.

Additional controls for potential artifacts were performed. Sections were stained with a positive control probe that targeted the peptidylprolyl isomerase B gene. This gene is ubiquitously expressed throughout the mice tissue (Kouadjo et al., 2007). In a parallel experiment, sections were stained with a probe that targeted the Bacillus subtilis dihydriodipicolinate reductase gene. This was used as a negative control because this bacterial gene is not expressed in mice. While peptidylprolyl isomerase B probe detected an mRNA species throughout the brain (Figures 1C,F), the negative control probe generated no fluorescence (data not shown) suggesting that the technique and conditions used do not create artifacts.

Detection of CCL5 mRNA in the Rat Brain

RNAscope® was then used to map the expression of CCL5 mRNA throughout the adult rat brain. Figures 2A–C show a schematic representation of three representative coronal
brain sections (0.20 mm, −3.30 mm and −5.30 mm from Bregma) where CCL5 mRNA was detected. Puncta were observed throughout the brain, although some regions contained more puncta than others (Table 1). For instance, the corpus callosum (cc, Figure 2A1) and the anterior commissure (Ac, Figure 2A3) contained more puncta than the caudate/putamen (CPu, Figure 2A2). In the cerebral cortex, more hybridization was observed in layers III/IV than II and VI (Figure 2B1). In the thalamus, the ventroposterior medial (VPM) nucleus exhibited more CCL5 mRNA hybridization than the ventroposterior lateral (VPL) nucleus (Figure 2B2). Within the hippocampus, CCL5 mRNA was more abundant in the fornix than in the hippocampal formation (Figures 2B3,B4). In the midbrain, areas with CCL5 mRNA signal included the cerebral peduncles (CP, Figure 2C2), and the ventral tegmental area (VTA, Figure 2C1).

Semi-quantitative analyses revealed that CCL5 mRNA is expressed in several brain regions, in agreement with previous studies (Campbell et al., 2013), but that there is an overall higher expression of CCL5 mRNA in areas containing fiber tracts. These include the corpus callosum, anterior commissure, external capsule, fimbria, optic tract and cerebral peduncle (Table 1). Moreover, we observed CCL5 mRNA positive signal in several brain areas, including the cerebral cortex, striatum, hippocampus, thalamus and midbrain (Table 1). Within these brain structures, CCL5 mRNA was detected only in selected areas. For instance, the piriform cortex was negative (Table 1). In the striatum, the dorsomedial portion exhibited more CCL5 mRNA signal than the ventromedial one (Table 1). Taken together, our data suggest that different cell type may express CCL5 mRNA.

### Glial Expression of CCL5 mRNA in the Corpus Callosum

Our semi-quantitative analysis indicates that CCL5 mRNA is most abundant in the white matter that contains fiber tracts (Table 1) which includes several subtypes of glial cells. To reveal which cells express CCL5 mRNA, we examined the corpus callosum utilizing RNAscope® in situ hybridization combined with immunohistochemistry for specific glial cell markers. These include GFAP, an astrocytic marker, Iba-1, a microglia/macrophage-specific marker, and Nkx2.2, a marker to identify oligodendrocyte progenitor cells. We found that CCL5 mRNA in the corpus callosum is predominantly inside nuclei of cells, evidenced by the co-localization of DAPI (blue) with the CCL5 mRNA hybridization signal, that were in GFAP (Figures 3A1–4), Iba-1 (Figures 3B1–4) and Nkx2.2 (Figures 3C1–4) positive cells. Noteworthy, Nkx2.2 positive cells were aligned in parallel rows (Figure 3C3), which is a typical property of adult oligodendrocyte progenitor cells. Quantitative analyses of CCL5 mRNA in the corpus callosum revealed that 53.3%, 31.4% and 72.4% of GFAP, Iba-1 and Nkx2.2 positive cells, respectively, expressed CCL5 mRNA while no CCL5 mRNA was found in neurons (Figure 4A). These results validate the notion that the corpus callosum contains a high percentage of oligodendrocytes expressing CCL5 mRNA.

### CCL5 mRNA Subcellular Distribution in the Cerebral Cortex

Analysis of the somatosensory cortex with the CCL5 probe revealed that layers III-V contained CCL5 mRNA, although most of the puncta were in layers III and IV (Figure 2B1). To characterize which cells express CCL5 mRNA in these layers, serial sections were examined by RNAscope® in situ hybridization combined with immunohistochemistry, using glial specific markers as described above. The neuron-specific nuclear protein marker, NeuN, was used to detect neurons. We observed that the fluorescent puncta of CCL5 mRNA were in layers III and IV were co-localized with NeuN (Figures 5A1–4), Iba-1 (Figures 5B1–4), as well as GFAP (Figures 5C1–4) positive cells. More positive puncta were observed in

### TABLE 1 | Relative levels of CCL5 mRNA.

| Brain regions                        | CCL5 mRNA |
|--------------------------------------|-----------|
| **White matter tracts**              |           |
| Corpus callosum                      | ++++      |
| External capsule                     | ++++      |
| Internal capsule                     | ++        |
| Fasculoculus retroflexus             | ++++      |
| Anterior comissure                   | ++++      |
| Medial lemniscus                     | +         |
| Optic tract                          | +++       |
| **Cerebral cortex**                  |           |
| Forelimb area                        | +         |
| Frontal cortex                       | +         |
| Parietal cortex                      | +         |
| Occipital cortex                     | +         |
| Cingulate cortex                     | ++++      |
| Piriform cortex                      | +         |
| Retrosplenial dysgranular cortex (RSG)| +         |
| Retrosplenial granular cortex (RSA)  | +         |
| **Septal nuclei/Caudate**            |           |
| Lateral septal nucleus               | +         |
| Vertical limb of diagonal band       | ++        |
| Dorsal caudate/putamen               | +         |
| Nucleus accumbens                    | +         |
| Entopontineural nucleus              | +         |
| **Hippocampus/Amygdala**             |           |
| Fimbria hippocampus (II)             | ++++      |
| CA1                                  | +         |
| CA2                                  | +         |
| CA3                                  | +         |
| Dentate gyrus (DG)                   | ++        |
| Amygdala                             | +         |
| **Thalamus/Hypothalamus**            |           |
| Laterodorsal thalamus, ventrolateral (LDVL)| +         |
| Ventral posterolateral thalamic nucleus (VPL) | +         |
| Ventral posteromedial thalamic nucleus (VPM) | ++++      |
| Hypothalamus                         | +         |
| **Midbrain**                         |           |
| Superior colliculus                  | +         |
| Cerebral peduncle                    | +         |
| Superior cerebellar peduncle/red nucleus | +++      |
| Substantia nigra pars compacta       | +         |
| Substantia nigra pars reticulata     | +         |
| Medial pretectal nucleus             | +         |
| Ventral tegmental area (VTA)         | +         |
| Periaqueductal gray                  | +         |

The levels of CCL5 mRNA are arbitrarily graded as occasional (+), low (++), moderate (+++), and high (++++) based on the intensity of hybridization signal.


glial cells (Figures 5B4,C4) than neurons (Figure 5A4), suggesting that cortical neurons express CCL5 mRNA in low abundance. Although we did not quantify CCL5 protein levels due to the lack of specificity of the antibodies, this result supports previous in vitro data that neurons produce and release CCL5 protein at a lower level than glial cells (Avdoshina et al., 2010). In layer V, CCL5 mRNA was also observed in Nkx2.2 positive cells (Figures 5D1–4), overall suggesting that in the cerebral cortex glia cell as well neurons express CCL5 mRNA. To confirm this finding, we carried out a quantitative analysis of CCL5 mRNA puncta, 48.9% of neurons, 44.1% of astrocytes, 12% of microglia and 13.3% oligodendrocytes were also positive for CCL5 mRNA (Figure 4B).

Neurons in the Hippocampus Express CCL5 mRNA
Analysis of the hippocampal formation revealed that CCL5 mRNA is particularly abundant in the fimbria (Figure 2B3), which is a prominent white matter tract along the edge of the hippocampus, supporting the notion that CCL5 mRNA is expressed in fiber tracts. However, red puncta were also observed in sections throughout the hippocampus mainly in the Cornu Ammonis (CA1) and dentate gyrus (DG) regions (Figure 2B4). The CA1 contains pyramidal neurons whereas the polymorphic layer of the DG consists of sparsely distributed polymorphic cells. RNAscope® in situ hybridization combined with immunohistochemistry revealed that in the CA1 region, in addition to neurons (Figures 6A1–4), microglia (Figures 6B1–4) and oligodendrocytes (Figures 6E1–4) expressed CCL5 mRNA. In neurons, the red puncta that correspond to CCL5 mRNA were found outside and inside the nuclei (Figure 6A4), suggesting that some of this mRNA is readily available for translation. In the polymorphic cells layer of the DG, microglia (Figures 6C1–4) and astrocytes (Figures 6D1–4) were positive for CCL5 mRNA. Overall, in the hippocampus, CCL5 mRNA was found in 73.2% of neurons and in ~20% in glial cells (Figure 4C).

CCL5 mRNA Is Expressed in a Subset of Dopaminergic Neurons in the Midbrain
CCL5 mRNA was also scattered in the midbrain (Figure 2C1). The majority of puncta were observed in the cerebral peduncle (Figure 2C), a major descending fiber tract. However, puncta were also observed within the VTA region. RNAscope® in situ
hybridization followed by immunohistochemistry revealed that in this region, 79% of neurons (Figure 4D) express CCL5 mRNA (Figures 7A1–4). Microglia (Figures 4D, 7B1–4), astrocytes (Figures 7D1–4), and few oligodendrocytes (Figures 4D, 7C1–4) also express CCL5 mRNA in 11.4%, 13.7%, and 5.9% respectively. Intriguingly, only a subpopulation of NeuN positive cells expressed CCL5 mRNA (Figure 7A3). To determine the type of neurons that express CCL5 mRNA, sections were stained with an antibody against TH, the rate limiting step enzyme for the synthesis of dopamine. Some but not all TH-positive cells exhibited CCL5 mRNA puncta (Figures 7E1–3), suggesting that CCL5 mRNA is synthesized in a small subset of dopamine neurons. Interestingly, these neurons, unlike those in the cerebral cortex, exhibited several puncta, mostly perinucleally (Figure 7E4), suggesting high expression of this mRNA in these neurons.

DISCUSSION

Our results reveal a unique expression profile of CCL5 mRNA throughout the adult rodent brain. We showed that the cellular anatomical distribution of this chemokine is highly regionalized and restricted to certain parts of the brain. Most notably, we found that CCL5 mRNA hybridization signal is the highest in white matter, such as the anterior commissure, corpus callosum and the optic tract, which are rich in glia cells and myelinated axons. However, a constitutive expression of CCL5 mRNA was also present in some subset of neuronal cell in the cerebral cortex and hippocampus, and especially in dopamine-producing neurons of the VTA. Altogether, our data characterize a constitutively anatomical and cellular expression of CCL5 mRNA in the rat brain. Most importantly, we observed CCL5 mRNA in various cells even without injury or inflammation.

Our work joins a growing number of studies that have shown that chemokines can be constitutively expressed throughout the brain in a region specific manner. For example, CX3CL1, the first chemokine shown to be expressed in neurons, is constitutively expressed in human (Raport et al., 1995) and rat brain (Nishiyori et al., 1998). CXCL12, also known as stromal derived factor-1, is expressed in different cell types throughout the rat brain, including astrocytes, microglia, and neurons (Banisadr et al., 2003). Similarly, CCL2 is constitutively expressed in neurons and astrocytes, but not in oligodendrocytes or microglia (Banisadr et al., 2005). Our data shows that under physiological conditions CCL5 mRNA is constitutively expressed in all glial cells (microglia, astrocytes and oligodendrocytes) as well as in a subset of neurons. Although in this work we only measured mRNA, the fact that CCL5 proteins are detected in the adult brain (Campbell et al., 2013) supports the notion that CCL5, like other chemokines (Banisadr et al., 2003), might have a role as potential modulators of brain function.

Under physiological conditions, CCL5 is expressed in low abundance in the brain tissue, posing an experimental challenge to detect it with conventional immunostaining technology. In addition, levels of a given peptide do not necessarily reflect the site of synthesis. An alternative approach is measuring mRNA by RNAscope® technology, which in addition to the sensitivity for the detection of low abundance mRNA
FIGURE 5 | Cell-specific localization of CCL5 mRNA in the cerebral cortex. RNAscope and immunohistochemistry were used to identify cells within the primary somatosensory cortex expressing CCL5 mRNA. (A1–3) Representative images of coronal sections showing the localization of CCL5 mRNA (red dots) in NeuN positive cells (green). Nuclei were counterstained with DAPI (blue). CCL5 mRNA (red dots) was also co-localized with Iba-1 (B1–3) and GFAP (C1–3) positive cells (green). Panels (D1–3) are examples of CCL5 mRNA signal (red dots) in Nkx2.2 (green) positive cells in layer V. Panels (A4–D4) are higher magnifications of the areas indicated by the arrows. Scale bar = 50 µm for (A1–D3); 20 µm for high magnification images (A4–D4).

molecules (Sørdal et al., 2013). In our study, we were able to observe low number of puncta within cells, as well as an agglomerate of puncta. The highest hybridization signal was mostly observed in glial cells. Moreover, in several sections, we have seen puncta in DAPI positive cells, suggesting a nuclear localization. However, CCL5 mRNA was also localized outside the nucleus. Thus, it appears that from the nucleus, CCL5 mRNA might move to the cytoplasm, where the translation into CCL5 protein occurs. This event could be followed by CCL5 release. Although measuring CCL5 release in vivo is technically challenging, this notion is supported by previous data showing that brain cells in vitro release CCL5 proteins (Avdoshina et al., 2010).

A novel discovery presented here is the expression of CCL5 mRNA in oligodendrocytes. The significance of this result is still under investigation. CCL5 promotes the proliferation of an oligodendrocyte precursor-like cell line (Kadi et al., 2006). Thus, it is possible that oligodendrocyte precursors or other glial cells might be regulating their own proliferation via the release of CCL5. Oligodendrocyte most well known role is to...
preserve myelin; however, oligodendrocytes also maintain axonal integrity, support axonal metabolism and aid neuronal survival (Peferoen et al., 2014). Changes in oligodendrocytes number and dynamics are increasingly recognized as important components in the pathogenesis of neurodegenerative disorders. In tauip rats, an animal model for multiple sclerosis, CCL5 and its receptor CCR5 is down-regulated in comparison to Sprague-Dawley rats (Soto-Rodriguez et al., 2015). Such reduction has been shown to limit the infiltration of pro-inflammatory macrophages and therefore to prevent demyelination (Glass et al., 2001). On the other hand, CCL5 has neuroprotective properties. For example, CCL5 has been shown to exert neuroprotective activity against various neurotoxins including glutamate (Bruno et al., 2000), β-amyloid (Ignatov et al., 2006), and the viral proteins gp120 (Campbell et al., 2015) and Tat (Rozzi et al., 2014). The neuroprotective activity of CCL5 could be due to its ability to increase neurotrophic factors, such as brain-derived neurotrophic factor and epidermal growth factor (Tokami et al., 2013). Thus, it is conceivable to suggest that oligodendrocyte-derived CCL5 could act as a regulator of neuronal survival.

Our studies showed that some neuronal populations in selected brain areas exhibit CCL5 mRNA. CCL5 is not the only chemokine that is expressed in neurons. For example, CCL2 is constitutively expressed in neurons, and co-localizes with various neurotransmitters and neuropeptides (Banisadr et al., 2005).
FIGURE 7 | Dopamine neurons express CCL5 mRNA. Representative images of coronal sections through the VTA. CCL5 mRNA (red dots) was detected in DAPI (blue) positive nuclei of neurons (A1–3), microglia (B1–3), oligodendrocytes (C1–3) and astrocytes (D1–3). CCL5 mRNA is also expressed in tyrosine hydroxylase (TH) positive cells (E1–3). Panels (A4–E4) are higher magnifications of areas pointed by arrows. Scale bar = 50 µm for (A1–E3), and 20 µm for high magnification images (A4–E4).

Also, CXCL12, CXCL14 and CX3CL1 are expressed in neurons in several brain regions (Nishiyori et al., 1998; Banisadr et al., 2011). In addition, neurons, at least in culture, are capable of releasing CCL5 upon depolarization or activation of N-methyl-D-aspartate receptors (Mocchetti et al., 2013), suggesting that neurons, under the proper stimulation, are capable of releasing CCL5, not dissimilar to that observed for neurotransmitters.

Here, we show that NeuN positive cells in the cerebral cortex and in the hippocampus are also CCL5 mRNA positive; together with previous findings that cortical neurons release CCL5 (Avdoshina et al., 2010), our data suggest that CCL5 mRNA can be translated into proteins in neurons. Moreover, few TH-positive cells in the VTA expressed CCL5 mRNA, indicating that CCL5 may be expressed by a subset of dopaminergic
neurons. Why CCL5 mRNA is detected only a subset of dopamine neurons is at present unclear. The VTA also contains GABAergic neurons (Dobi et al., 2010). Thus, the co-localization of CCL5 mRNA in TH-negative but NeuN positive cells in the VTA suggests that CCL5 mRNA may be synthetized in GABAergic neurons. More experiments are needed to support this suggestion.

Our data show that CCL5 mRNA is contained in a subset of dopaminergic neurons. The significance of this finding remains speculative at present. Dopamine neurons of the VTA belong to the dopaminergic mesolimbic system, which comprises several interconnected brain regions, including the nucleus accumbens and the prefrontal cortex. Activation of this system is crucial for the reward and addictive properties of opioids (Wise and Rompre, 1989; Pontieri et al., 1995). We have previously shown that CCL5 protein levels are increased in morphine dependent rats in brain areas involved in opioid reward (Campbell et al., 2013). CCL5 has also been shown to interact with opioid receptors causing heterologous desensitization (Szabo et al., 2002). Thus, CCL5, when produced in dopaminergic fibers innervating the nucleus accumbens or prefrontal cortex could be contributing to regulation of dependence to opioids as previously suggested (Campbell et al., 2013). CCL5 might act as a neuromodulator to enhance/inhibit the synaptic transmission underlying opioid reward. Although still speculative, this suggestion is supported by data showing that CCR5, the receptor for CCL5, is expressed in selected neuronal populations of the frontal cortex and striatum (Avdoshina et al., 2011). Moreover, CCL5 increases the release of glutamate (Musante et al., 2008; Di Prisco et al., 2012) whose activity could induce various forms of synaptic plasticity and cellular adaptations that are responsible for opioid tolerance and addiction (Manzoni and Williams, 1999; Stuber et al., 2010, 2011).

In conclusion, we were able to detect CCL5 mRNA by in situ hybridization in adult rat brain in several cells, including a subset of neurons. Together with previous results showing that CCL5 and its receptor CCR5 are constitutively produced in the adult rodent brain (Tran et al., 2007; Avdoshina et al., 2011; Campbell et al., 2013), our data suggest a role for CCL5 in the CNS other than a homeostatic chemokine that attracts and activates mononuclear phagocytes at sites of inflammation.

AUTHOR CONTRIBUTIONS

MFL, IM and SV designed the experiments and wrote the manuscript. MFL and SV performed the in situ hybridization and immunofluorescence experiments and analyzed the data. IM, SV and MPB revised the manuscript. All authors reviewed the results and approved the final version of the manuscript.

FUNDING

This work was supported by the Dean of Biomedical Research (Toulmin pilot project) provided by the Georgetown University Medical Center (IM), NIH grants R03 NS095038 (SV), R01 NS082308 (MPB) and R21 NS089446 (IM) from the National Institute for Neurological Disorders and Stroke.

ACKNOWLEDGMENTS

The authors would like to thank Dr. Valeria Avdoshina for comments on the manuscript and Kierra S. Jenkins for technical support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnana.2017.00137/full#supplementary-material

FIGURE S1 | Examples of brain sections from wild-type (WT) and CCL5 knock-out (KO) mice stained for CCL5 using different commercially available antibodies. (A,B) 25H14L17 (1:2000, Thermo Fisher), (C,D) NSBP1-19769 (1:1500, Sigma-Aldrich). Please note that all antibodies detect CCL5-like immunoreactivity in KO mice. At higher dilutions, all antibodies failed to detect CCL5 immunoreactivity.

REFERENCES

Adler, M. W., Geller, E. B., Chen, X., and Rogers, T. J. (2005). Viewing chemokines as a third major system of communication in the brain. AAPS J. 7, E865–E870. doi: 10.1208/aapsj070484
Avdoshina, V., Becker, J., Campbell, L., Parsadanian, M., Mhyre, T., Tessarollo, L., et al. (2011). Neurotrophins modulate the expression of chemokine receptors in the brain. J. Neurovirol. 17, 58–62. doi: 10.1007/s13365-010-0004-3
Avdoshina, V., Biggio, F., Palchik, G., Campbell, L. A., and Mocchetti, I. (2010). Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. Glia 58, 1630–1639. doi: 10.1002/glia.21035
Bakhiet, M., Tjernlund, A., Mousa, A., Gad, A., Strömblad, S., Kuziel, W. A., et al. (2001). RANTES promotes growth and survival of human first-trimester forebrain astrocytes. Nat. Cell Biol. 3, 150–157. doi: 10.1038/35050570
Balabanov, R., Strand, K., Goswami, R., McMahon, E., Begolka, W., Miller, S. D., et al. (2007). Interferon-γ-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J. Neurosci. 27, 2013–2024. doi: 10.1523/JNEUROSCI.4689-06.2007
Banisadr, G., Bhattacharyya, B. J., Belmadani, A., Izen, S. C., Ren, D., Tran, P. B., et al. (2011). The chemokine BRAK/CXCL14 regulates synaptic transmission in the adult mouse dentate gyrus stem cell niche. J. Neurochem. 119, 1173–1182. doi: 10.1111/j.1471-4159.2011.07509.x
Banisadr, G., Gosselin, R. D., Mechighel, P., Kitabgi, P., Rostene, W., and Parsadaniantz, S. M. (2005). Highly regionalized neuronal expression of monocytic chemoattractant protein-1 (MCP-1/CCL2) in rat brain: evidence for its colocalization with neurotransmitters and neuropeptides. J. Comp. Neurol. 489, 275–292. doi: 10.1002/cne.20598
Banisadr, G., Skrzydelski, D., Kitabgi, P., Rostène, W., and Parsadaniantz, S. M. (2003). Highly regionalized neuronal expression of monocytic chemoattractant protein-1 (MCP-1/CCL2) in rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur. J. Neurosci. 18, 1593–1606. doi: 10.1046/j.1460-9586.2003.02893.x
Lanfranco et al. CCL5 mRNA in the Rat Brain

Bhangoo, S., Ren, D., Miller, R. J., Henry, K. J., Lineswala, J., Hamdouchi, C., et al. (2007). Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Mol. Pain 3:38. doi: 10.1186/1744-8069-3-38

Bolin, L. M., Murray-Teixeira, D., Lukac, N. W., Strietter, R. M., Kunkel, S. L., Schall, T. J., et al. (1998). Primary sensory neurons migrate in response to the chemokine RANTES. J. Neuroimmunol. 81, 49–57. doi: 10.1016/S0165-5728(97)00158-6

Bruno, V., Copani, A., Besong, G., Scoto, G., and Nicoletti, F. (2000). Neuroprotective activity of chemokines against N-methyl-D-aspartate or β-amyloid-induced toxicity in culture. Eur. J. Pharmacol. 399, 117–121. doi: 10.1016/s0014-2999(00)00367-8

Campbell, L. A., Avdoshiva, V., Day, C., Lim, S. T., and Mocchetti, I. (2015). Pharmacological induction of CCL5 in vivo prevents gp120-mediated neuronal injury. Neuropharmacology 92, 98–107. doi: 10.1016/j.neuropharm.2015.01.009

Campbell, L. A., Avdoshiva, V., Rozzi, S., and Mocchetti, I. (2013). CCL5 and cytokine expression in the rat brain: differential modulation by chronic morphine and morphine withdrawal. Brain Behav. Immun. 34, 130–140. doi: 10.1016/j.bbi.2013.08.006

Chou, S. Y., Ajoy, R., Changou, C. A., Hsieh, Y. T., Wang, Y. K., and Hoffer, B. (2016). CCL5/RANTES contributes to hypothalamic insulin signaling for systemic insulin responsiveness through CC-CKR. Sci. Rep. 6:37659. doi: 10.1038/srep37659

Conant, K., GARZINO-Demo, A., Nath, A., McArthur, J. C., Halliday, W., Power, C., et al. (1999). Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc. Natl. Acad. Sci. U.S.A 95, 3117–3121. doi: 10.1073/pnas.95.6.3117

Di Prisco, S., Summa, M., Chellakudam, V., Rossi, P. I., and Pittaluga, A. (2012). RANTES-mediated control of excitatory acid amino release in mouse spinal cord. J. Neurochem. 121, 428–437. doi: 10.1111/j.1471-4159.2012.07720.x

Dobi, A., Margolis, E. B., Wang, H.-L., Harvey, B. K., and Morales, M. (2010). Glutamatergic and nonglutamatergic neurons of the ventral tegmental area corelease glutamate. J. Basic Clin. Physiol. Pharmacol. 21, 185–189. doi: 10.1515/jbcpp-2013-0121

Grabiniski, T. M., Kneynsberg, A., Manfredsson, F. P., and Kanaan, N. M. (2015). A method for combining RNAscope in situ hybridization with immunohistochemistry in thick free-floating brain sections and primary neuronal cultures. PLoS One 10:e0120120. doi: 10.1371/journal.pone.0120120

He, J., Chen, Y., Farzan, M., Choe, H., Ohagen, A., Gartner, S., et al. (1997). CCRI and CCRII are co-receptors for HIV-1 infection of microglia. Nature 385, 645–649. doi: 10.1038/385654a0

Hvas, J., McLean, C., Justesen, J., Kannourakis, G., Steinman, L., Oksenberg, J. R., et al. (1997). Perivascular T cells express the pro-inflammatory chemokine RANTES mRNA in multiple sclerosis lesions. Scand. J. Immunol. 46, 195–203. doi: 10.1111/j.1365-3083.1997.d0101-x

Ignatov, A., Robert, J., Gregory-Evans, C., and Schaller, H. C. (2006). RANTES Hvas, J., McLean, C., Justesen, J., Kannourakis, G., Steinman, L., Oksenberg, J. R., et al. (2006). Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a retroviral neurotropic coronavirus. J. Neurosci. 28, 88–187. doi: 10.1006/jnro.2001.1050

Rentzos, M., Nikolau, C., Rombos, A., Boufidou, F., Musante, V., Longordo, F., et al. (2007). Delayed functional expression of neuronal chemokine receptors in the “shell” as compared with the “core” of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A 92, 12303–12308. doi: 10.1073/pnas.92.26.12304

Raport, C. J., Schweickart, L. V., Eddy, R. L. Jr., Shows, T. B., and Gray, P. W. (1995). The orphan G-protein-coupled receptor-encoding gene V28 is closely related to genes for chemokine receptors and is expressed in lymphoid and neural tissues. Gene 193, 295–299. doi: 10.1016/0378-1119(95)00336-5

Rentszos, M., Nikolau, C., Rombos, A., Boufidou, F., Zoga, M., Di Chiara, G. (1995). Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the “shell” as compared with the “core” of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A 92, 12304–12308. doi: 10.1073/pnas.92.26.12304

Santangelo, E., et al. (2014). Cerebral stroke injury: the role of cytokines and receptors expression profile in the myelin mutant taiep rat. Expert Opin. Ther. Targets 18, 131–137. doi: 10.1515/eott-2013-0121

Schmidtmayerova, H., Nottet, H. S., Nuovo, G., Raabe, T., Flanagan, C. R., and Brosnan, C. F. (1998). MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J. Neuroinflammation 86, 20–29. doi: 10.1016/s1655-7289(98)00002-2

Simplicia, L., Gallelli, L., Malferrari, G., Pirritano, D., Serra, R., Santangelo, E., et al. (2014). Cerebral stroke injury: the role of cytokines and brain inflammation. J. Basic Clin. Physiol. Pharmacol. 25, 131–137. doi: 10.1515/jbcpp-2013-0121

Soto-Rodriguez, G., Gonzalez-Barrios, J. A., Martinez-Fong, D., Blanco-Alvarez, V. M., Egibar, J. R., Ugarté, A., et al. (2015). Analysis of chemokines and receptors expression profile in the myelin mutant taiep rat. Oxid. Med. Cell. Longev. 2015:397310. doi: 10.1155/2015/397310

Ting, G. D., Hnasko, T. S., Britt, J. F., Edwards, R. H., and Bonci, A. (2010). Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate. J. Neurosci. 30, 8229–8233. doi: 10.1523/JNEUROSCI.1754-10.2010
Stuber, G. D., Sparta, D. R., Stamatakis, A. M., van Leeuwen, W. A., Hardjoprajitno, J., Cho, S., et al. (2011). Excitatory transmission from the amygdala to nucleus accumbens facilitates reward seeking. *Nature* 475, 377–380. doi: 10.1038/nature10194

Szabo, I., Chen, X. H., Xin, L., Adler, M. W., Howard, O. M., Oppenheim, J. J., et al. (2002). Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. *Proc. Natl. Acad. Sci. U S A* 99, 10276–10281. doi: 10.1073/pnas.102327699

Tokami, H., Ago, T., Sugimori, H., Kuroda, J., Awano, H., Suzuki, K., et al. (2013). RANTES has a potential to play a neuroprotective role in an autocrine/paracrine manner after ischemic stroke. *Brain Res.* 1517, 122–132. doi: 10.1016/j.brainres.2013.04.022

Tran, P. B., Banisadr, G., Ren, D., Chenn, A., and Miller, R. J. (2007). Chemokine receptor expression by neural progenitor cells in neurogenic regions of mouse brain. *J. Comp. Neurol.* 500, 1007–1033. doi: 10.1002/cne.21229

Ubogu, E. E., Callahan, M. K., Tucky, B. H., and Ransohoff, R. M. (2006). Determinants of CCL5-driven mononuclear cell migration across the blood–brain barrier. Implications for therapeutically modulating neuroinflammation. *J. Neuroimmunol.* 179, 132–144. doi: 10.1016/j.jneuroim.2006.06.004

Villapol, S., Loane, D. J., and Burns, M. P. (2017). Sexual dimorphism in the inflammatory response to traumatic brain injury. *Glia* 65, 1423–1438. doi: 10.1002/glia.23171

White, F. A., Bhangoo, S. K., and Miller, R. J. (2005). Chemokines: integrators of pain and inflammation. *Nat. Rev. Drug Discov.* 4, 834–844. doi: 10.1038/nrd1852

Wise, R. A., and Rompre, P. P. (1989). Brain dopamine and reward. *Annu. Rev. Psychol.* 40, 191–225. doi: 10.1146/annurev.psych.40.1.191

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2018 Lanfranco, Moccheti, Burns and Villapol. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*